Viridian Therapeutics(VRDN) Seeking Alpha·2024-12-17 17:41Core Insights - Viridian Therapeutics is included in the model portfolio of the Biotech Forum, which is currently offering a one-month trial at half the regular price [1] - The company had key catalysts that were anticipated, with one being disclosed recently, resulting in a stock price increase of just over a certain percentage [2] Company Overview - Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a biopharmaceutical company that is actively monitored by investment analysts [2] - The Biotech Forum, led by Bret, provides a model portfolio featuring 12-20 high upside biotech stocks, along with live discussions and weekly updates [2] Investment Position - The analyst has a beneficial long position in the shares of VRDN, indicating confidence in the company's future performance [3]